ストックスクリーナーアプリを入手
0.0249
23.88%
0.0048
Geovax Labs Inc (GOVXW) 最新ニュース
GeoVax to Present at the Emerging Growth Conference on July 16, 2025 - Yahoo Finance
GeoVax Labs (NASDAQ:GOVX) Upgraded by Wall Street Zen to “Hold” Rating - Defense World
Why Did GeoVax Labs Inc. (GOVX) Soar 10.34%? - AInvest
Roth MKM Keeps Their Buy Rating on GeoVax Labs (GOVX) - The Globe and Mail
Vaccine Co. Secures European Regulatory Breakthrough Potential - streetwisereports.com
GeoVax Labs (NASDAQ:GOVX) Cut to “Sell” at Wall Street Zen - Defense World
GeoVax Labs Announces $6 Million Public Offering - The Globe and Mail
GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives - Yahoo Finance
GeoVax Announces $6 Million Public Offering to Advance Immunotherapies and Vaccines - citybuzz -
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection - Yahoo Finance
GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy - Yahoo Finance
Financial Health Check: Examining Geovax Labs Inc (GOVX)’s Key Ratios - DWinneX
Why Beyond Air Shares Are Trading Lower By Over 23%; Here Are 20 Stocks Moving Premarket - Benzinga
Geovax Labs Inc Inc. (GOVX) Price Performance: Is It Undervalued or Overvalued? - investchronicle.com
GeoVax Labs (GOVX) Gains Positive EMA Feedback, Potential Speedier Approval | GOVX Stock News - GuruFocus
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting - Yahoo Finance
GeoVax Advances Toward European Approval for Mpox and Smallpox Vaccine with EMA's Support - citybuzz -
GeoVax Labs’ (GOVX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
GeoVax Labs (GOVX) Issues New Stock Units with Warrants | GOVX Stock News - GuruFocus
GeoVax Labs (GOVX) Gains EMA Approval for Phase 3 Vaccine Trial | GOVX Stock News - GuruFocus
GOVX: Geovax Labs Receives Buy Rating from Analyst | GOVX Stock News - GuruFocus
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA - Yahoo Finance
GeoVax to Showcase Innovative Vaccines and Therapies at BIO International Convention 2025 - citybuzz -
GeoVax to Participate in BIO International Convention 2025 - Yahoo Finance
Geovax highlights progress on mpox vaccine and COVID-19 trial advancements - MSN
GeoVax Advances GEO-MVA Vaccine Development Amid WHO's Mpox Emergency Declaration - citybuzz -
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency - Yahoo Finance
Robinhood Markets, Inc. Reports May 2025 Operating Data - The Globe and Mail
GeoVax to Showcase Positive Immune Response Data for GEO-CM04S1 in CLL Patients at EHA 2025 Congress - citybuzz -
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients - Yahoo Finance
42,275 Shares in GeoVax Labs, Inc. (NASDAQ:GOVX) Acquired by Citadel Advisors LLC - Defense World
GeoVax’s Multi-Antigen COVID-19 Vaccine Candidates Show Promise Against Variants - citybuzz -
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia - Yahoo Finance
Northern Trust Corp Invests $29,000 in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology - Yahoo Finance
GeoVax Labs, Inc. (NASDAQ:GOVX) Receives Average Recommendation of “Buy” from Analysts - Defense World
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing - Yahoo Finance
GeoVax Labs (NASDAQ:GOVX) Shares Up 6.9% – Should You Buy? - Defense World
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance - Yahoo Finance
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation - Yahoo Finance
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations - Yahoo Finance
What caused GOVX's Q2 2024 profit turnaround? - AInvest
GeoVax Labs (GOVX) Projected to Post Earnings on Tuesday - Defense World
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025 - Yahoo Finance
GeoVax Strengthens Patent Portfolio for Innovative Cancer Therapy Approach - citybuzz -
GeoVax Expands Gedeptin(R) Patent Portfolio - Yahoo Finance
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production - Yahoo Finance
MarketsMedicine Hat News - FinancialContent
GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia - ADVFN
D. Boral Capital Cuts GeoVax Labs (NASDAQ:GOVX) Price Target to $9.00 - Defense World
GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Form 8-KCurrent report - ADVFN
Geode Capital Management LLC Has $223,000 Holdings in GeoVax Labs, Inc. (NASDAQ:GOVX) - Defense World
Analysts Offer Insights on Healthcare Companies: GeoVax Labs (GOVX) and Baxter International (BAX) - The Globe and Mail
GeoVax Labs Earnings Call: Mixed Sentiment and Future Prospects - TipRanks
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOV - GuruFocus
Geovax Labs (GOVX) Faces Price Target Reduction by Analyst | GOVX Stock News - GuruFocus
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
0.02%
2.05%
大文字化:
|
ボリューム (24 時間):